Recent Updates
Recently added Catalysts

DEX PS DDS

Phase 2

Diabetes | Small molecule | Metabolic |AbbVie Inc.|Last Updated: May 30, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment315
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00035906Research Study in Patients With Persistent Macular EdemaPHASE2 COMPLETED 315Oct 1, 2001Aug 1, 2004May 30, 20111 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
DEX PS DDS®DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion: Persistent macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion, or Irvine-Gass syndrome, persisting at least 90 days after laser treatment or medical management by a physician. Exclusion: Females who are pregnant or lactating, and females of childbearing p...

Countries:United States
Unlock Eligibility Criteria